Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks

Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity

This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity

iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health

This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings

Healthium and C-CAMP launch innovations program for surgical and medical technologies

Indoco Remedies receives final USFDA approval for rivaroxaban tablets

Rivaroxaban is used to treat venous thromboembolism

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide

Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India